About aytu biopharma inc - AYTU
Aytu BioPharma, Inc. is a specialty pharmaceutical company, which engages in identifying, acquiring, and commercializing novel products. Its products include EXXUA, Adzenys XR-ODT, Cotempla XR-ODT, Karbinal ER, and Metadate CD. The company was founded on August 9, 2002 and is headquartered in Denver, CO.
AYTU At a Glance
Aytu BioPharma, Inc.
7900 East Union Avenue
Denver, Colorado 80237
| Phone | 1-720-437-6580 | Revenue | 57.57M | |
| Industry | Pharmaceuticals: Major | Net Income | -14,252,000.00 | |
| Sector | Health Technology | Employees | 76 | |
| Fiscal Year-end | 06 / 2027 | |||
| View SEC Filings |
AYTU Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 0.46 |
| Price to Book Ratio | 0.654 |
| Price to Cash Flow Ratio | 8.07 |
| Enterprise Value to EBITDA | -4.17 |
| Enterprise Value to Sales | 0.318 |
| Total Debt to Enterprise Value | 0.99 |
AYTU Efficiency
| Revenue/Employee | 757,500.00 |
| Income Per Employee | -187,526.316 |
| Receivables Turnover | 2.527 |
| Total Asset Turnover | 0.501 |
AYTU Liquidity
| Current Ratio | 1.13 |
| Quick Ratio | 1.004 |
| Cash Ratio | 0.481 |
AYTU Profitability
| Gross Margin | 59.625 |
| Operating Margin | -14.443 |
| Pretax Margin | -24.719 |
| Net Margin | -24.756 |
| Return on Assets | -12.413 |
| Return on Equity | -52.552 |
| Return on Total Capital | -26.699 |
| Return on Invested Capital | -37.469 |
AYTU Capital Structure
| Total Debt to Total Equity | 51.33 |
| Total Debt to Total Capital | 33.919 |
| Total Debt to Total Assets | 17.21 |
| Long-Term Debt to Equity | 28.219 |
| Long-Term Debt to Total Capital | 18.647 |